Zealand Pharma Adds Up To $1.2 Billion Generate Alliance, Broadening Its Obesity Modalities After Mixed Readouts

Zealand Pharma has turned to Generate:Biomedicines to add AI-designed protein therapeutics to its obesity and metabolic disease pipeline in a deal that could reach nearly $1.2 billion. Zealand will pay $30 million upfront, and Generate could receive up to $35 million in early preclinical milestones for the two initial partnered programs.

Under the agreement, Generate will use its AI-enabled platform to design and develop multispecific protein therapeutics, handling research through candidate selection or lead-candidate selection before Zealand takes over clinical development, regulatory work and commercialization. In addition to the upfront and early preclinical payments, the package includes nearly $1.2 billion in development, regulatory and commercial milestones and tiered royalties on worldwide net sales of any resulting commercial products.

The move matters less as a one-off licensing announcement than as a modality decision. Zealand’s pipeline has been built on peptide research and, more recently, small molecules through its December partnership with OTR Therapeutics. By adding proteins through Generate, Zealand is widening the set of tools it can use in metabolic disease and polypharmacology rather than relying only on the mechanisms and formats that already dominate its obesity portfolio.

The Commercial Picture

The timing also reflects pressure on Zealand to refresh the obesity narrative around assets that are already more advanced but have not clearly exceeded investor expectations. Zealand’s lead obesity programs are partnered with Roche and Boehringer Ingelheim, and both are in Phase 3, yet recent data have drawn muted reactions.

Last week, Zealand reported Phase 2 ZUPREME-2 results for the long-acting amylin analog petrelintide in 220 patients with obesity or overweight who also had type 2 diabetes. At 28 weeks, patients on petrelintide saw up to a 9.2% mean weight loss versus 2% for placebo, and the drug reduced A1c by up to 0.65% versus a 0.23% increase in placebo. While the study hit its main goal, William Blair said it was “disappointed” that petrelintide did not produce greater weight loss and pointed to A1c reductions of 1.3% to 2.1% seen with Eli Lilly’s Zepbound and Novo’s Wegovy.

Earlier this month, Zealand and Boehringer Ingelheim reported up to 13.1% weight loss at 76 weeks for survodutide, the glucagon/GLP-1 receptor dual agonist that Boehringer licensed from Zealand in 2011. Investors also found those findings underwhelming, sending Zealand’s shares down 8% in the aftermath.

Against that backdrop, the Generate deal looks like an attempt to create future shots on goal in obesity rather than depend entirely on assets that are already setting expectations in public markets. AI is the enabling technology here, but the business point is portfolio diversification across modalities.

The Road Here

Generate brings a platform that has already produced a late-stage internal asset. The Massachusetts-based biotech, founded in 2018 by Flagship Pioneering, went public in February with $425 million intended to support Phase 3 development of GB-0895, an anti-TSLP therapy for severe asthma. GB-0895, which is also in early-stage studies for chronic obstructive pulmonary disease, was designed using Generate’s generative AI platform.

Phase 1 data disclosed last month showed that a single subcutaneous injection of GB-0895 led to what the company described as rapid and sustained reductions in asthma biomarkers through six months of follow-up, while also lowering disease biomarkers in COPD. The study’s primary outcome, tolerability, was favorable, with treatment-emergent adverse events balanced between GB-0895 and placebo groups.

Generate also has platform collaborations with Novartis and Amgen, and its pipeline includes the MMAE-targeting antibody GB-4362 and the armored CAR T therapy GB-5267 in early-stage development. That history does not validate any metabolic candidate before it is made, but it does show that larger drugmakers are willing to pay for Generate’s ability to generate proteins that can advance into the clinic.

For Zealand, that may be the most practical value of this deal: not a quick fix for recent obesity readouts, but a way to import a protein-design capability that could produce differentiated candidates in a category where incremental efficacy gaps are becoming more visible.